pocketful logo light
pocketful logo light
Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523

₹5436.50

(0.61%)

Fri, 29 May 2026, 05:25 am

mtf coin illustrationMTF 5x

Company History

1973

  • The Company was incorporated as a private limited company 'Alkem Laboratories Private Limited'.

1978

  • The Company established its first plant at Taloja, Maharashtra.

1988

  • The Company became a deemed public limited company.

1992

  • The Company established its manufacturing facility in Mandwa, Maharashtra.

1998

  • The Company established its Kachigam manufacturing facility in Gujarat.

2001

  • Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company.

2002

  • The Company established its Amaliya manufacturing facility in Gujarat.
  • The Company was awarded the Pharma Business and Technology Excellence Award as 'India's Most Esteemed Pharmaceutical Company'.

2003

  • The Company set up its research and development facility at Taloja, Maharashtra.

2004

  • The product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand.

2005

  • The Company established its manufacturing facility in Baddi, Himachal Pradesh.
  • The Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards.
  • The facility in Mandwa, Maharashtra was converted into an API facility.

2006

  • The anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India.

2007

  • The Company established its manufacturing facility in Kumrek, Sikkim.
  • The Company filed its first ANDA in the United States for the drug Amlodipine.
  • The Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra.

2009

  • The Company acquired Pharmacor, a generic pharma company in Australia.
  • The Company received a certificate of appreciation for outstanding export performance in the category of formulations.
  • The Company received a certificate of appreciation in the category of 'Formulation Experts'.

2010

  • The Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC.

2011

  • The Company acquired Enzene Bio sciences Limited.

2012

  • The Company acquired an API manufacturing facility in the United States.

2013

  • The Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit.

2014

  • The Company acquired Clindac.
  • The product 'Clavam' was awarded as the 'Brand of the Year' at the AWACS Award, 2014.

2015

  • The Company acquired a formulation manufacturing facility in the United States.

2016

  • Alkem's Mandva Plant obtained the Establishment Inspection Report from the US FDA.
  • Alkem received the EIR from the US FDA for its Daman formulation facility.

2017

  • Alkem formed a marketing alliance with Haw Par to exclusively market, sell, and distribute the Tiger Balam range of products in India.
  • Alkem started direct consumer marketing for Pregakem and Livoerb.
  • Alkem received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.

2018

  • Alkem's revenue from the US market crossed USD 200 million in annual sales.
  • The brand 'Clavam' received the 'Brand of the Year 2018' award at AWACS AWARDS FOR Marketing Excellence.

2019

  • Alkem crossed the revenue milestone of USD 1 billion.
  • Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019.
  • Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.

2020

  • Alkem launched Favipiravir in India under the brand name 'Alfluenza'.
  • Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.

2021

  • Alkem launched Ibuprofen and Famotidine Tablets in the United States.
  • Alkem launched Perampanel Tablets in India under the brand name 'Perampil'.
  • Alkem launched Brivaracetam in India under the brand name 'Brivasure'.
  • Alkem partnered with Tata Memorial Hospital.
  • Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.

2022

  • Alkem signed a license agreement with Harvard University's Office of Technology Development.

2023

  • The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005.
  • The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.